MacroZyme B.V. developed products for treatment of metabolic diseases, notably type II diabetes. This serious disease affects a rapidly growing number of people worldwide, especially in conjunction with obesity.
Portfolio: MedSciences Capital B.V.
Current stage: product portfolio sold to Genzyme Corporation.